Fimasartan Ameliorates Deteriorations in Glucose Metabolism in a High Glucose State by Regulating Skeletal Muscle and Liver Cells
Since diabetes and hypertension frequently occur together, it is thought that these conditions may have a common pathogenesis. This study was designed to evaluate the anti-diabetic function of the anti-hypertensive drug fimasartan on C2C12 mouse skeletal muscle and HepG2 human liver cells in a high...
Saved in:
| Published in: | Yonsei medical journal Vol. 63; no. 6; pp. 530 - 538 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Korea (South)
Yonsei University College of Medicine
01-06-2022
연세대학교의과대학 |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Since diabetes and hypertension frequently occur together, it is thought that these conditions may have a common pathogenesis. This study was designed to evaluate the anti-diabetic function of the anti-hypertensive drug fimasartan on C2C12 mouse skeletal muscle and HepG2 human liver cells in a high glucose state.
The anti-diabetic effects and mechanism of fimasartan were identified using Western blot, glucose uptake tests, oxygen consumption rate (OCR) analysis, adenosine 5'-triphosphate (ATP) enzyme-linked immunosorbent assay (ELISA), and immunofluorescence staining for diabetic biomarkers in C2C12 cells. Protein biomarkers for glycogenolysis and glycogenesis were evaluated by Western blotting and ELISA in HepG2 cells.
The protein levels of phosphorylated 5' adenosine monophosphate-activated protein kinase (p-AMPK), p-AKT, insulin receptor substrate-1 (IRS-1), and glucose transporter type 4 (Glut4) were elevated in C2C12 cells treated with fimasartan. These increases were reversed by peroxisome proliferator-activated receptor delta (PPARδ) antagonist. ATP, OCR, and glucose uptake were increased in cells treated with 200 µM fimasartan. Protein levels of glycogen phosphorylase, glucose synthase, phosphorylated glycogen synthase, and glycogen synthase kinase-3 (GSK-3) were decreased in HepG2 cells treated with fimasartan. However, these effects were reversed following the addition of the PPARδ antagonist GSK0660.
In conclusion, fimasartan ameliorates deteriorations in glucose metabolism as a result of a high glucose state by regulating PPARδ in skeletal muscle and liver cells. |
|---|---|
| AbstractList | PURPOSESince diabetes and hypertension frequently occur together, it is thought that these conditions may have a common pathogenesis. This study was designed to evaluate the anti-diabetic function of the anti-hypertensive drug fimasartan on C2C12 mouse skeletal muscle and HepG2 human liver cells in a high glucose state. MATERIALS AND METHODSThe anti-diabetic effects and mechanism of fimasartan were identified using Western blot, glucose uptake tests, oxygen consumption rate (OCR) analysis, adenosine 5'-triphosphate (ATP) enzyme-linked immunosorbent assay (ELISA), and immunofluorescence staining for diabetic biomarkers in C2C12 cells. Protein biomarkers for glycogenolysis and glycogenesis were evaluated by Western blotting and ELISA in HepG2 cells. RESULTSThe protein levels of phosphorylated 5' adenosine monophosphate-activated protein kinase (p-AMPK), p-AKT, insulin receptor substrate-1 (IRS-1), and glucose transporter type 4 (Glut4) were elevated in C2C12 cells treated with fimasartan. These increases were reversed by peroxisome proliferator-activated receptor delta (PPARδ) antagonist. ATP, OCR, and glucose uptake were increased in cells treated with 200 µM fimasartan. Protein levels of glycogen phosphorylase, glucose synthase, phosphorylated glycogen synthase, and glycogen synthase kinase-3 (GSK-3) were decreased in HepG2 cells treated with fimasartan. However, these effects were reversed following the addition of the PPARδ antagonist GSK0660. CONCLUSIONIn conclusion, fimasartan ameliorates deteriorations in glucose metabolism as a result of a high glucose state by regulating PPARδ in skeletal muscle and liver cells. Purpose: Since diabetes and hypertension frequently occur together, it is thought that these conditions may have a common pathogenesis. This study was designed to evaluate the anti-diabetic function of the anti-hypertensive drug fimasartan on C2C12 mouseskeletal muscle and HepG2 human liver cells in a high glucose state. Materials and Methods: The anti-diabetic effects and mechanism of fimasartan were identified using Western blot, glucose uptaketests, oxygen consumption rate (OCR) analysis, adenosine 5'-triphosphate (ATP) enzyme-linked immunosorbent assay (ELISA),and immunofluorescence staining for diabetic biomarkers in C2C12 cells. Protein biomarkers for glycogenolysis and glycogenesiswere evaluated by Western blotting and ELISA in HepG2 cells. Results: The protein levels of phosphorylated 5' adenosine monophosphate-activated protein kinase (p-AMPK), p-AKT, insulinreceptor substrate-1 (IRS-1), and glucose transporter type 4 (Glut4) were elevated in C2C12 cells treated with fimasartan. These increaseswere reversed by peroxisome proliferator-activated receptor delta (PPARδ) antagonist. ATP, OCR, and glucose uptake wereincreased in cells treated with 200 μM fimasartan. Protein levels of glycogen phosphorylase, glucose synthase, phosphorylated glycogensynthase, and glycogen synthase kinase-3 (GSK-3) were decreased in HepG2 cells treated with fimasartan. However, theseeffects were reversed following the addition of the PPARδ antagonist GSK0660. Conclusion: In conclusion, fimasartan ameliorates deteriorations in glucose metabolism as a result of a high glucose state by regulatingPPARδ in skeletal muscle and liver cells. KCI Citation Count: 0 Since diabetes and hypertension frequently occur together, it is thought that these conditions may have a common pathogenesis. This study was designed to evaluate the anti-diabetic function of the anti-hypertensive drug fimasartan on C2C12 mouse skeletal muscle and HepG2 human liver cells in a high glucose state. The anti-diabetic effects and mechanism of fimasartan were identified using Western blot, glucose uptake tests, oxygen consumption rate (OCR) analysis, adenosine 5'-triphosphate (ATP) enzyme-linked immunosorbent assay (ELISA), and immunofluorescence staining for diabetic biomarkers in C2C12 cells. Protein biomarkers for glycogenolysis and glycogenesis were evaluated by Western blotting and ELISA in HepG2 cells. The protein levels of phosphorylated 5' adenosine monophosphate-activated protein kinase (p-AMPK), p-AKT, insulin receptor substrate-1 (IRS-1), and glucose transporter type 4 (Glut4) were elevated in C2C12 cells treated with fimasartan. These increases were reversed by peroxisome proliferator-activated receptor delta (PPARδ) antagonist. ATP, OCR, and glucose uptake were increased in cells treated with 200 µM fimasartan. Protein levels of glycogen phosphorylase, glucose synthase, phosphorylated glycogen synthase, and glycogen synthase kinase-3 (GSK-3) were decreased in HepG2 cells treated with fimasartan. However, these effects were reversed following the addition of the PPARδ antagonist GSK0660. In conclusion, fimasartan ameliorates deteriorations in glucose metabolism as a result of a high glucose state by regulating PPARδ in skeletal muscle and liver cells. |
| Author | Seo, Hong Seog Han, Yoon Mi Kim, Hyun Min Park, Seung Yeon Lee, Yong Jik Jeong, Ji Hoon Jang, Yoo Na Jung, Tae Woo |
| AuthorAffiliation | 6 Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Korea 3 Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Korea 1 Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea 4 Laboratory of Genomics and Translational Medicine, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea 5 Department of Medical Science, Korea University College of Medicine, Seoul, Korea 2 Department of Medicine, Graduate School, College of Medicine, Chung-Ang University, Seoul, Korea |
| AuthorAffiliation_xml | – name: 6 Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Korea – name: 4 Laboratory of Genomics and Translational Medicine, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea – name: 2 Department of Medicine, Graduate School, College of Medicine, Chung-Ang University, Seoul, Korea – name: 3 Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Korea – name: 5 Department of Medical Science, Korea University College of Medicine, Seoul, Korea – name: 1 Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Yoo Na orcidid: 0000-0002-0014-9783 surname: Jang fullname: Jang, Yoo Na organization: Department of Medicine, Graduate School, College of Medicine, Chung-Ang University, Seoul, Korea – sequence: 2 givenname: Yong Jik orcidid: 0000-0001-8814-0099 surname: Lee fullname: Lee, Yong Jik organization: Laboratory of Genomics and Translational Medicine, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea – sequence: 3 givenname: Yoon Mi orcidid: 0000-0002-1554-4823 surname: Han fullname: Han, Yoon Mi organization: Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea – sequence: 4 givenname: Hyun Min orcidid: 0000-0001-8807-0764 surname: Kim fullname: Kim, Hyun Min organization: Department of Medical Science, Korea University College of Medicine, Seoul, Korea – sequence: 5 givenname: Hong Seog orcidid: 0000-0002-3228-7988 surname: Seo fullname: Seo, Hong Seog email: mdhsseo@korea.ac.kr organization: Department of Medical Science, Korea University College of Medicine, Seoul, Korea. mdhsseo@korea.ac.kr – sequence: 6 givenname: Ji Hoon orcidid: 0000-0001-8257-403X surname: Jeong fullname: Jeong, Ji Hoon organization: Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Korea – sequence: 7 givenname: Seung Yeon orcidid: 0000-0002-3850-0567 surname: Park fullname: Park, Seung Yeon organization: Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Korea – sequence: 8 givenname: Tae Woo orcidid: 0000-0002-1167-1892 surname: Jung fullname: Jung, Tae Woo email: twjung@cau.ac.kr organization: Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Korea. twjung@cau.ac.kr |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35619576$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002841592$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNpVkUtvGyEUhVGVqnHS_oBuKpbtYqY8DJhNJcttHpKjSon3iMF3HGKGSWEmkpf958V2arWrK7jnO5fLuUBnsY-A0EdKas6n-uuue6oZYayWvJa14OQNmlCtZMWmXJ2hCRGUV0JpeY4ucn4ihClK2Dt0zoWkWig5Qb-vfGezTYONeN5B8H2yA2T8HQZIh4PvY8Y-4uswuj4DvoPBNn3wudvfWnzjN4-n5sNQaNzs8D1sxlDguMEPWwiFCfhuzC4AtnGNl_4FEl5ACPk9etvakOHDa71Eq6sfq8VNtfx5fbuYLyvHZ2Ko2pmb2alrlG2t44y30MKalzUstYLxpmFQ-opMVQMWGieBEMWnYi1aazXwS_TlaBtTa7bOm976Q930ZpvM_H51a7RWggldtN-O2uex6WDtIA7JBvOcyl-l3YH8vxP9Y_F5MZoqKhUvBp9fDVL_a4Q8mM5nV7a1EfoxGyYVZWrGtCpSepS61OecoD2NocTsUzYlZbNP2UhupCkpF-bTv-87EX9j5X8AjJ-pOQ |
| Cites_doi | 10.1124/pr.114.010454 10.1007/BF00400248 10.1128/MCB.00983-10 10.1152/ajpendo.00194.2007 10.1126/science.1104343 10.1016/S0092-8674(00)81106-X 10.1042/bj20030048 10.1186/1743-7075-10-63 10.1016/0003-9861(83)90432-0 10.1016/j.cmet.2009.03.012 10.1016/j.biocel.2005.03.002 10.1038/emm.2015.122 10.1073/pnas.0501559102 10.1146/annurev.nutr.19.1.379 10.1074/jbc.M702329200 10.1016/j.beem.2016.06.001 10.1155/2008/679137 10.1096/fj.03-0269fje 10.2337/db06-1135 10.1101/gad.8.10.1224 10.1007/s00011-015-0895-9 10.1111/j.1524-6175.2005.05264.x 10.1111/j.1582-4934.2010.01085.x 10.1007/s12272-012-0700-z 10.1146/annurev.nutr.22.010402.102912 10.1038/hr.2017.67 10.1101/gad.178434.111 10.1177/1358863X14521315 10.1016/0026-0495(87)90242-3 10.1111/dom.13282 10.1161/01.CIR.0000127955.36250.65 10.1007/s11906-996-0011-1 10.1016/j.bbrc.2012.08.093 10.1016/j.phymed.2012.03.006 10.1161/01.HYP.0000078490.59735.6E 10.1016/j.febslet.2007.11.040 10.1186/1475-2840-11-139 10.1074/jbc.M303946200 10.1152/ajpendo.00391.2014 10.13005/bpj/1758 10.1161/01.HYP.0000253968.95136.b8 10.1155/2013/549627 10.7150/ijms.13187 10.1136/bmj.317.7160.703 |
| ContentType | Journal Article |
| Copyright | Copyright: Yonsei University College of Medicine 2022. Copyright: Yonsei University College of Medicine 2022 2022 Yonsei University College of Medicine |
| Copyright_xml | – notice: Copyright: Yonsei University College of Medicine 2022. – notice: Copyright: Yonsei University College of Medicine 2022 2022 Yonsei University College of Medicine |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM ACYCR |
| DOI | 10.3349/ymj.2022.63.6.530 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index (Open Access) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1976-2437 |
| EndPage | 538 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9975259 10_3349_ymj_2022_63_6_530 35619576 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Korea University Guro Hospital – fundername: Korea University Medical Center grantid: O1801781 – fundername: Chung-Ang University – fundername: ; – fundername: ; grantid: O1801781 |
| GroupedDBID | --- .55 .GJ 123 29R 2WC 36B 5-W 53G 5RE 8JR 8XY 9ZL ACYCR ADBBV ADRAZ AEGXH AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CGR CS3 CUY CVF DIK DU5 E3Z EBD ECM EF. EIF EMB EMOBN F5P GROUPED_DOAJ GX1 HYE KQ8 L7B M48 MK0 M~E NPM O5R O5S OK1 P2P PGMZT RNS RPM SV3 TR2 X7M XSB ZGI ZXP AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c385t-f8c8a4cb7afac323fefed3619a1a523bb2e8a47047beaebc6e007345d5faa9e3 |
| IEDL.DBID | RPM |
| ISSN | 0513-5796 |
| IngestDate | Tue Nov 21 21:46:33 EST 2023 Tue Sep 17 21:06:38 EDT 2024 Fri Aug 16 08:26:23 EDT 2024 Fri Aug 23 03:58:00 EDT 2024 Wed Oct 16 00:41:19 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Fimasartan glucose metabolism angiotensin II type 1 receptor blocker PPARδ |
| Language | English |
| License | Copyright: Yonsei University College of Medicine 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c385t-f8c8a4cb7afac323fefed3619a1a523bb2e8a47047beaebc6e007345d5faa9e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Yoo Na Jang and Yong Jik Lee contributed equally to this work. https://www.eymj.org/DOIx.php?id=10.3349/ymj.2022.63.6.530 |
| ORCID | 0000-0001-8814-0099 0000-0001-8807-0764 0000-0001-8257-403X 0000-0002-3850-0567 0000-0002-1167-1892 0000-0002-0014-9783 0000-0002-3228-7988 0000-0002-1554-4823 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171673/ |
| PMID | 35619576 |
| PQID | 2671278297 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9975259 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9171673 proquest_miscellaneous_2671278297 crossref_primary_10_3349_ymj_2022_63_6_530 pubmed_primary_35619576 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-06-01 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Yonsei medical journal |
| PublicationTitleAlternate | Yonsei Med J |
| PublicationYear | 2022 |
| Publisher | Yonsei University College of Medicine 연세대학교의과대학 |
| Publisher_xml | – name: Yonsei University College of Medicine – name: 연세대학교의과대학 |
| References | Horr (10.3349/ymj.2022.63.6.530_ref4) 2016; 30 Amoghimath (10.3349/ymj.2022.63.6.530_ref45) 2019; 12 Hales (10.3349/ymj.2022.63.6.530_ref3) 1992; 35 Cho (10.3349/ymj.2022.63.6.530_ref29) 2008; 2008 Sica (10.3349/ymj.2022.63.6.530_ref11) 2002; 4 Smith (10.3349/ymj.2022.63.6.530_ref12) 2005; 37 Long (10.3349/ymj.2022.63.6.530_ref24) 2011; 31 Furuhashi (10.3349/ymj.2022.63.6.530_ref17) 2003; 42 Shiota (10.3349/ymj.2022.63.6.530_ref18) 2012; 11 Savoia (10.3349/ymj.2022.63.6.530_ref10) 2007; 49 Tatsumi (10.3349/ymj.2022.63.6.530_ref6) 2017; 40 Lowell (10.3349/ymj.2022.63.6.530_ref35) 2005; 307 UK Prospective Diabetes Study Group (10.3349/ymj.2022.63.6.530_ref5) 1998; 317 Luquet (10.3349/ymj.2022.63.6.530_ref34) 2003; 17 Kelley (10.3349/ymj.2022.63.6.530_ref13) 2002; 22 Nordlie (10.3349/ymj.2022.63.6.530_ref14) 1999; 19 Karnik (10.3349/ymj.2022.63.6.530_ref8) 2015; 67 Yang (10.3349/ymj.2022.63.6.530_ref21) 2016; 65 Chellan (10.3349/ymj.2022.63.6.530_ref1) 2012; 19 Gan (10.3349/ymj.2022.63.6.530_ref39) 2011; 25 Rutter (10.3349/ymj.2022.63.6.530_ref28) 2003; 375 McInnes (10.3349/ymj.2022.63.6.530_ref38) 2013; 10 Akatsuka (10.3349/ymj.2022.63.6.530_ref41) 1983; 220 Schupp (10.3349/ymj.2022.63.6.530_ref31) 2004; 109 Woods (10.3349/ymj.2022.63.6.530_ref27) 2003; 278 Lee (10.3349/ymj.2022.63.6.530_ref19) 2017; 2017 Tontonoz (10.3349/ymj.2022.63.6.530_ref32) 1994; 8 Hartman (10.3349/ymj.2022.63.6.530_ref40) 2014; 19 Feng (10.3349/ymj.2022.63.6.530_ref44) 2011; 15 Prasannarong (10.3349/ymj.2022.63.6.530_ref15) 2012; 426 Favre (10.3349/ymj.2022.63.6.530_ref16) 2015; 308 Yang (10.3349/ymj.2022.63.6.530_ref23) 2018; 20 Tisch (10.3349/ymj.2022.63.6.530_ref2) 1996; 85 Rong (10.3349/ymj.2022.63.6.530_ref36) 2007; 56 Kim (10.3349/ymj.2022.63.6.530_ref20) 2015; 12 Krämer (10.3349/ymj.2022.63.6.530_ref33) 2007; 282 Kim (10.3349/ymj.2022.63.6.530_ref7) 2012; 35 Monsalve (10.3349/ymj.2022.63.6.530_ref30) 2013; 2013 Han (10.3349/ymj.2022.63.6.530_ref42) 2016; 48 De Taeye (10.3349/ymj.2022.63.6.530_ref22) 2007; 293 Zhang (10.3349/ymj.2022.63.6.530_ref25) 2009; 9 Mårin (10.3349/ymj.2022.63.6.530_ref43) 1987; 36 Chrysant (10.3349/ymj.2022.63.6.530_ref9) 2006; 8 Short (10.3349/ymj.2022.63.6.530_ref37) 2005; 102 Reilly (10.3349/ymj.2022.63.6.530_ref26) 2008; 582 |
| References_xml | – volume: 67 start-page: 754 year: 2015 ident: 10.3349/ymj.2022.63.6.530_ref8 publication-title: Pharmacol Rev doi: 10.1124/pr.114.010454 contributor: fullname: Karnik – volume: 35 start-page: 595 year: 1992 ident: 10.3349/ymj.2022.63.6.530_ref3 publication-title: Diabetologia doi: 10.1007/BF00400248 contributor: fullname: Hales – volume: 31 start-page: 430 year: 2011 ident: 10.3349/ymj.2022.63.6.530_ref24 publication-title: Mol Cell Biol doi: 10.1128/MCB.00983-10 contributor: fullname: Long – volume: 293 start-page: E713 year: 2007 ident: 10.3349/ymj.2022.63.6.530_ref22 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00194.2007 contributor: fullname: De Taeye – volume: 307 start-page: 384 year: 2005 ident: 10.3349/ymj.2022.63.6.530_ref35 publication-title: Science doi: 10.1126/science.1104343 contributor: fullname: Lowell – volume: 85 start-page: 291 year: 1996 ident: 10.3349/ymj.2022.63.6.530_ref2 publication-title: Cell doi: 10.1016/S0092-8674(00)81106-X contributor: fullname: Tisch – volume: 375 start-page: 1 year: 2003 ident: 10.3349/ymj.2022.63.6.530_ref28 publication-title: Biochem J doi: 10.1042/bj20030048 contributor: fullname: Rutter – volume: 10 start-page: 63 year: 2013 ident: 10.3349/ymj.2022.63.6.530_ref38 publication-title: Nutr Metab (Lond) doi: 10.1186/1743-7075-10-63 contributor: fullname: McInnes – volume: 220 start-page: 426 year: 1983 ident: 10.3349/ymj.2022.63.6.530_ref41 publication-title: Arch Biochem Biophys doi: 10.1016/0003-9861(83)90432-0 contributor: fullname: Akatsuka – volume: 9 start-page: 407 year: 2009 ident: 10.3349/ymj.2022.63.6.530_ref25 publication-title: Cell Metab doi: 10.1016/j.cmet.2009.03.012 contributor: fullname: Zhang – volume: 37 start-page: 2047 year: 2005 ident: 10.3349/ymj.2022.63.6.530_ref12 publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2005.03.002 contributor: fullname: Smith – volume: 48 start-page: e218 year: 2016 ident: 10.3349/ymj.2022.63.6.530_ref42 publication-title: Exp Mol Med doi: 10.1038/emm.2015.122 contributor: fullname: Han – volume: 102 start-page: 5618 year: 2005 ident: 10.3349/ymj.2022.63.6.530_ref37 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0501559102 contributor: fullname: Short – volume: 19 start-page: 379 year: 1999 ident: 10.3349/ymj.2022.63.6.530_ref14 publication-title: Annu Rev Nutr doi: 10.1146/annurev.nutr.19.1.379 contributor: fullname: Nordlie – volume: 282 start-page: 19313 year: 2007 ident: 10.3349/ymj.2022.63.6.530_ref33 publication-title: J Biol Chem doi: 10.1074/jbc.M702329200 contributor: fullname: Krämer – volume: 30 start-page: 445 year: 2016 ident: 10.3349/ymj.2022.63.6.530_ref4 publication-title: Best Pract Res Clin Endocrinol Metab doi: 10.1016/j.beem.2016.06.001 contributor: fullname: Horr – volume: 2017 start-page: 8048720 year: 2017 ident: 10.3349/ymj.2022.63.6.530_ref19 publication-title: PPAR Res contributor: fullname: Lee – volume: 2008 start-page: 679137 year: 2008 ident: 10.3349/ymj.2022.63.6.530_ref29 publication-title: PPAR Res doi: 10.1155/2008/679137 contributor: fullname: Cho – volume: 17 start-page: 2299 year: 2003 ident: 10.3349/ymj.2022.63.6.530_ref34 publication-title: FASEB J doi: 10.1096/fj.03-0269fje contributor: fullname: Luquet – volume: 56 start-page: 1751 year: 2007 ident: 10.3349/ymj.2022.63.6.530_ref36 publication-title: Diabetes doi: 10.2337/db06-1135 contributor: fullname: Rong – volume: 8 start-page: 1224 year: 1994 ident: 10.3349/ymj.2022.63.6.530_ref32 publication-title: Genes Dev doi: 10.1101/gad.8.10.1224 contributor: fullname: Tontonoz – volume: 65 start-page: 115 year: 2016 ident: 10.3349/ymj.2022.63.6.530_ref21 publication-title: Inflamm Res doi: 10.1007/s00011-015-0895-9 contributor: fullname: Yang – volume: 8 start-page: 261 year: 2006 ident: 10.3349/ymj.2022.63.6.530_ref9 publication-title: J Clin Hypertens (Greenwich) doi: 10.1111/j.1524-6175.2005.05264.x contributor: fullname: Chrysant – volume: 15 start-page: 1572 year: 2011 ident: 10.3349/ymj.2022.63.6.530_ref44 publication-title: J Cell Mol Med doi: 10.1111/j.1582-4934.2010.01085.x contributor: fullname: Feng – volume: 35 start-page: 1123 year: 2012 ident: 10.3349/ymj.2022.63.6.530_ref7 publication-title: Arch Pharm Res doi: 10.1007/s12272-012-0700-z contributor: fullname: Kim – volume: 22 start-page: 325 year: 2002 ident: 10.3349/ymj.2022.63.6.530_ref13 publication-title: Annu Rev Nutr doi: 10.1146/annurev.nutr.22.010402.102912 contributor: fullname: Kelley – volume: 40 start-page: 795 year: 2017 ident: 10.3349/ymj.2022.63.6.530_ref6 publication-title: Hypertens Res doi: 10.1038/hr.2017.67 contributor: fullname: Tatsumi – volume: 25 start-page: 2619 year: 2011 ident: 10.3349/ymj.2022.63.6.530_ref39 publication-title: Genes Dev doi: 10.1101/gad.178434.111 contributor: fullname: Gan – volume: 19 start-page: 67 year: 2014 ident: 10.3349/ymj.2022.63.6.530_ref40 publication-title: Vasc Med doi: 10.1177/1358863X14521315 contributor: fullname: Hartman – volume: 36 start-page: 1154 year: 1987 ident: 10.3349/ymj.2022.63.6.530_ref43 publication-title: Metabolism doi: 10.1016/0026-0495(87)90242-3 contributor: fullname: Mårin – volume: 20 start-page: 1670 year: 2018 ident: 10.3349/ymj.2022.63.6.530_ref23 publication-title: Diabetes Obes Metab doi: 10.1111/dom.13282 contributor: fullname: Yang – volume: 109 start-page: 2054 year: 2004 ident: 10.3349/ymj.2022.63.6.530_ref31 publication-title: Circulation doi: 10.1161/01.CIR.0000127955.36250.65 contributor: fullname: Schupp – volume: 4 start-page: 321 year: 2002 ident: 10.3349/ymj.2022.63.6.530_ref11 publication-title: Curr Hypertens Rep doi: 10.1007/s11906-996-0011-1 contributor: fullname: Sica – volume: 426 start-page: 369 year: 2012 ident: 10.3349/ymj.2022.63.6.530_ref15 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2012.08.093 contributor: fullname: Prasannarong – volume: 19 start-page: 730 year: 2012 ident: 10.3349/ymj.2022.63.6.530_ref1 publication-title: Phytomedicine doi: 10.1016/j.phymed.2012.03.006 contributor: fullname: Chellan – volume: 42 start-page: 76 year: 2003 ident: 10.3349/ymj.2022.63.6.530_ref17 publication-title: Hypertension doi: 10.1161/01.HYP.0000078490.59735.6E contributor: fullname: Furuhashi – volume: 582 start-page: 26 year: 2008 ident: 10.3349/ymj.2022.63.6.530_ref26 publication-title: FEBS Lett doi: 10.1016/j.febslet.2007.11.040 contributor: fullname: Reilly – volume: 11 start-page: 139 year: 2012 ident: 10.3349/ymj.2022.63.6.530_ref18 publication-title: Cardiovasc Diabetol doi: 10.1186/1475-2840-11-139 contributor: fullname: Shiota – volume: 278 start-page: 28434 year: 2003 ident: 10.3349/ymj.2022.63.6.530_ref27 publication-title: J Biol Chem doi: 10.1074/jbc.M303946200 contributor: fullname: Woods – volume: 308 start-page: E435 year: 2015 ident: 10.3349/ymj.2022.63.6.530_ref16 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00391.2014 contributor: fullname: Favre – volume: 12 start-page: 1303 year: 2019 ident: 10.3349/ymj.2022.63.6.530_ref45 publication-title: Biomed Pharmacol J doi: 10.13005/bpj/1758 contributor: fullname: Amoghimath – volume: 49 start-page: 341 year: 2007 ident: 10.3349/ymj.2022.63.6.530_ref10 publication-title: Hypertension doi: 10.1161/01.HYP.0000253968.95136.b8 contributor: fullname: Savoia – volume: 2013 start-page: 549627 year: 2013 ident: 10.3349/ymj.2022.63.6.530_ref30 publication-title: Mediators Inflamm doi: 10.1155/2013/549627 contributor: fullname: Monsalve – volume: 12 start-page: 891 year: 2015 ident: 10.3349/ymj.2022.63.6.530_ref20 publication-title: Int J Med Sci doi: 10.7150/ijms.13187 contributor: fullname: Kim – volume: 317 start-page: 703 year: 1998 ident: 10.3349/ymj.2022.63.6.530_ref5 publication-title: BMJ doi: 10.1136/bmj.317.7160.703 contributor: fullname: UK Prospective Diabetes Study Group |
| SSID | ssj0027102 |
| Score | 2.3524973 |
| Snippet | Since diabetes and hypertension frequently occur together, it is thought that these conditions may have a common pathogenesis. This study was designed to... PURPOSESince diabetes and hypertension frequently occur together, it is thought that these conditions may have a common pathogenesis. This study was designed... Purpose: Since diabetes and hypertension frequently occur together, it is thought that these conditions may have a common pathogenesis. This study was designed... |
| SourceID | nrf pubmedcentral proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 530 |
| SubjectTerms | Adenosine Triphosphate - metabolism Animals Biphenyl Compounds Glucose - metabolism Glycogen Synthase Kinase 3 - metabolism Glycogen Synthase Kinase 3 - pharmacology Humans Liver - metabolism Mice Muscle, Skeletal Original PPAR delta - metabolism PPAR delta - pharmacology Pyrimidines Tetrazoles 의학일반 |
| Title | Fimasartan Ameliorates Deteriorations in Glucose Metabolism in a High Glucose State by Regulating Skeletal Muscle and Liver Cells |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35619576 https://search.proquest.com/docview/2671278297 https://pubmed.ncbi.nlm.nih.gov/PMC9171673 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002841592 |
| Volume | 63 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Yonsei Medical Journal, 2022, 63(6), , pp.530-538 |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELboHhAXxJvwWBnECSlpG8d2clx1tywSRYjdAzfLdmw2NHFXTXvYI_-cmTyqXcSJU6Q4UWJ_48w38TdjQj6ADwTeq22cgy-CAMXaWLNyFsP3WAtrhPcWA8XzC_n1R356hmVy-JgL04n2ramSUDdJqK46beV1Y6ejTmz6bbUosMaLZNMJmQA3HEP0Mcqad0JDMDYWY6Jlv5TJWFZMb5pfEBGmaSJYIhLOcBs4BgSi4Fhy5JZfmoSt_xfl_Fs5ecsVLR-RhwOHpCf9uz4m91x4Qu6vhlXyp-T3smp0C13RgZ40rsYsfGCU9BSlL9WAeUurQD_1gnW6cjswhrpqGzyrKao_Do0dH6Xmhn7v960HZ0cv1uCugLfT1b6Fd6A6lPQLSjzowtV1-4xcLs8uF-fxsNVCbFnOd7HPba4za6T22rKUeeddyWBk9FxDqGpM6qBdzjJpnHbGCodLfBkvude6cOw5OQqb4F4S6suswLKP3MBMN0IXBnN7c2lkxmU2yyLycRxndd0X1FAQiCA-CvBRiI8STAkF-ETkPSCh1rZSWAYbjz83ar1VQPY_q6KQHKK3iLwbgVIwN3DBQwe32bcqFXKeSkwejsiLHrjDM0fcIyLvQHq4AB94twXMsau_PZjfq_--8zV5gN3sFWdvyNFuu3dvyaQt98fdP4HjzqL_AIHm-8w |
| link.rule.ids | 230,315,729,782,786,866,887,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwELa6qdT2kj7T0qdb9VQJlsWA4Rhtst2oS1Q1e-jNso1p6YI3WnYPOeafd4bHKql6ygkJY4H5xp755G_GhHwGHwhxr9RuAr4ICIrWrmS578J6LGOt4qLQSBTnF_z8Z3JyimVyoiEXphXta1V6tqo9W_5utZWXtR4POrHx92yaYo0XzsYjch_mq-8PJH3gWZNWagjmxlxMtew2MxkL0_FV_Qc4YRB4MfNiL2J4EByDECKNsOjIDc80spvif0Hnv9rJG85o9viOw3hCDvvokx53zU_JPWOfkQdZv7_-nFzPylo20FtaelybCvP3IRalJyiaKXtraWhp6ddO6k4zswUzqsqmxruSom5k39hGslRd0R_diffgJunFChwdRPw02zXwDVTanC5QHEKnpqqaF2Q5O11O525_SIOrWRJt3SLRiQy14rKQmgWsMIXJGfxROZFAcpUKDLRzP-TKSKN0bHBzMIzyqJAyNeyIHNi1Na8ILfIwxYKRkYI1QsUyVZgVnHDFw4iHfuiQLwM-4rIrxSGAwiCuAnAViKuImYgF4OqQT4CgWOlSYAFtvP5ai9VGAE04E2nKI-B9Dvk4ACxgVuFWibRmvWtEEPNJwDHt2CEvO8D37xzsxSH8linsH8AX3m4BC2grd_eIv75zzw_k4XyZLcTi7PzbG_IIh9zp1t6Sg-1mZ96RUZPv3rfz4S9GOhBw |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07b9swECbqFAi69P1Qn2zRqYAkW5REaQzsuAkaB0GToRtBUmSrWqINyx4y9p_3Tg8jKTq1kwCREkV9R9594McjIR_BB0LcK7WfgS8CgqK1L1kx9mE-lqlWqbUaieLJJT__ls2OMU3O_qivVrSvVRm4qg5c-aPVVq5rHQ46sfBiMc0xxwtn4bqw4YjchTE7jgaiPnCtSSs3BJNjPm637BY0GYvz8Lr-CbwwioKUBWmQMDwMjkEYkSeYeOSGdxq5jf1b4PmnfvKGQ5o_-I-uPCT3-yiUHnVVHpE7xj0mh4t-nf0J-TUva9nAG6SjR7WpcB8_xKR0huKZsreahpaOfu4k73RhtmBOVdnUeFdS1I_sC9uIlqpr-rU7-R7cJb1cgsODyJ8udg18A5WuoGcoEqFTU1XNU3I1P76anvj9YQ2-Zlmy9W2mMxlrxaWVmkXMGmsKBn9VTiSQXaUiA-V8HHNlpFE6NbhIGCdFYqXMDXtGDtzKmReE2iLOMXFkomCuUKnMFe4OzrjiccLjceyRTwNGYt2l5BBAZRBbAdgKxFakTKQCsPXIB0BRLHUpMJE2Xr-vxHIjgC6cijznCfA_j7wfQBYwunDJRDqz2jUiSvkk4rj92CPPO9D3bQ424xF-yxz2FbDB2yVgBW0G7x71l__85DtyeDGbi7PT8y-vyD3scSdfe00OtpudeUNGTbF72w6J38oIEvA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fimasartan+Ameliorates+Deteriorations+in+Glucose+Metabolism+in+a+High+Glucose+State+by+Regulating+Skeletal+Muscle+and+Liver+Cells&rft.jtitle=Yonsei+medical+journal&rft.au=Jang%2C+Yoo+Na&rft.au=Lee%2C+Yong+Jik&rft.au=Han%2C+Yoon+Mi&rft.au=Kim%2C+Hyun+Min&rft.date=2022-06-01&rft.eissn=1976-2437&rft.volume=63&rft.issue=6&rft.spage=530&rft.epage=538&rft_id=info:doi/10.3349%2Fymj.2022.63.6.530&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon |